Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
eb613 save search
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 2.3%
H: 1.25%
C: -2.5%
eb613 publication research bone trial
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 12.18%
H: 0.0%
C: -11.43%
eb613 fda expected osteoporosis key milestone
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
Published: 2023-11-29 (Crawled : 13:30) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 2.55%
H: 1.42%
C: -2.88%
eb613 osteoporosis treatment ongoing potential results study platform
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
Published: 2023-11-09 (Crawled : 20:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -2.78%
eb613 fda osteoporosis milestone
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613)
Published: 2023-08-16 (Crawled : 13:00) - biospace.com/
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 11.85%
H: 0.0%
C: -6.11%
eb613
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
Published: 2023-08-16 (Crawled : 12:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 11.85%
H: 0.0%
C: -6.11%
eb613 treatment risk research women meeting bone
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
Published: 2023-04-03 (Crawled : 20:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 3.45%
H: 0.0%
C: -16.25%
eb613 fda meeting program
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Published: 2023-02-15 (Crawled : 15:20) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 2.34%
H: 9.2%
C: 8.45%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -0.06%
eb613 treatment meeting review osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published: 2022-10-06 (Crawled : 12:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: -7.08%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.56%
H: 0.27%
C: -0.68%
eb613 treatment fda trial agreement
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
Published: 2022-09-21 (Crawled : 13:00) - biospace.com/
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 0.0%
H: 7.73%
C: 6.61%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.62%
H: 0.65%
C: -2.04%
eb613 treatment impact potential osteoporosis
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 0.72%
H: 6.43%
C: 0.0%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
eb613 correlation meeting response study osteoporosis
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 613
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
Published: 2022-01-04 (Crawled : 14:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 8.57%
H: 0.0%
C: -10.17%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
eb613 fda phase 2 bone 613 spine phase 3
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 0.82%
H: 5.26%
C: 4.88%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.01%
H: 0.25%
C: -0.98%
presentation phase 2 osteoporosis eb613
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting
Published: 2021-08-02 (Crawled : 13:15) - biospace.com/
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 5.4%
H: 2.66%
C: 1.71%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.37%
H: 0.15%
C: -0.96%
treatment phase 2 bone eb613 research osteoporosis
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 60.58%
H: 20.39%
C: -9.85%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.11%
H: 0.04%
C: -0.39%
phase 2 topline eb613 dmd
Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
Published: 2020-12-10 (Crawled : 14:03) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: 26.36%
H: 8.63%
C: -14.39%
fda approval fda approval hormone treatment eb613 osteoporosis application
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.